The Liver Disease Panel includes LiverPRO—a certified algorithm developed by the health tech company Evido—requiring only age and routine blood markers for the timely detection of liver fibrosis With ...
Chronic liver disease poses a growing global health burden, driven in large part by metabolic risk factors and viral hepatitis. Fibrosis stage is the principal ...
Non-invasive biomarkers and scoring systems demonstrated effectiveness in differentiating chronic liver disease (CLD) from cirrhosis; non-invasive fibrosis scores such as the Lok index, King's score, ...
Roche announced the launch of its comprehensive Liver Disease Panel, a suite of certified algorithms designed to help clinicians better identify and manage chronic liver disease (CLD). By bringing ...
Non-invasive indicators of liver fibrosis could help with risk stratification for heart failure. The median follow-up duration was 10.7 years. For all three measures of liver fibrosis, the risk for ...
"[We] have conducted a large individual participant data meta-analysis and shown that screening strategies using sequential application of simple NITs like FIB-4 or NFS followed by LSM-VCTE achieve ...
Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO-a certified algorithm ...
Roche announced the launch of its comprehensive Liver Disease Panel, a suite of certified algorithms designed to help clinicians better identify and manage chronic liver disease (CLD). By bringing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results